• Explore /
  • Poster
  • / Pivotal phase III COMPOSE trial will compare <sup>177</sup>Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors.

Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors.

Abstract Poster

Authors

Thorvardur Ragnar Halfdanarson

Thorvardur Ragnar Halfdanarson

Division of Medical Oncology, Mayo Clinic, Rochester, MN

Thorvardur Ragnar Halfdanarson , Diane Lauren Reidy , Namrata Vijayvergia , Daniel M. Halperin , Grace Goldstein , Grace Kong , Michael Michael , Simone Leyden , Simona Grozinsky-Glasberg , Halfdan Sorbye , Kjell E. Oberg , Cristina Sierras , Philip Harris

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04919226

DOI

10.1200/JCO.2022.40.4_suppl.TPS514

Abstract #

TPS514

Poster Bd #

P5

Abstract Disclosures

Similar Posters

First Author: Aman Chauhan

First Author: Estephany Abou Jokh Casas

First Author: Robert Lance Fine

First Author: Nick Pavlakis